EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy

Zhangfang Li iD, Yaosheng Luo iD, Quandi Huang, Zhi Chen, Dandan Song, Daoyan Pan, Shidi Hu, Wei Jiang, Qiuyue Cai, Xiaoting Feng, Qing Zhang, Chanyan Weng und 5 weitere

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgad476 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Zhangfang Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Methylprednisolone, Graves Ophthalmopathy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Southern Medical University, Guangdong Science and Technology Plan Project, China Health Promotion Foundation Thyroid Research Project for Young and Middle-aged Doctors.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Intravenous glucocorticoid (IVGC) is an accessible and affordable treatment for Graves orbitopathy (GO); the 4.5-g protocol is well studied, but many details of treatment protocols need to be clarified.

Objective

To compare the efficacy and safety of weekly and monthly protocol of IVGC in GO.

Methods

A prospective, randomized, observer-masked, single-center clinical trial, followed up to week 24, at the third affiliated hospital of Southern Medical University; 58 patients with active and moderate to severe GO, aged 18-60 years old, who had not received relevant treatment were included. The intervention was weekly protocol or monthly protocol of IVGC; both received a cumulative dose of methylprednisolone 4.5 g and had a duration of 12 weeks. The overall effective rate, improvement of quality of life (QOL) and signal intensity ratio (SIR) were measured.

Results

There was no significant difference in the effective rate between the 2 groups at week 12 and week 24 (86.21% vs 72.41%, P = .195; 86.21% vs 82.61%, P = .441), there was no significant difference in the improvement of clinical activity score, exophthalmos, soft tissue involvement, diplopia, and QOL. At week 24, the mean SIR and maximum SIR of the 2 groups were lower than those before treatment, and there were no statistically significant difference between the 2 groups. There was no significant difference in the incidence of adverse events between the 2 groups (31.03% vs 27.59%, P = .773).

Conclusion

The efficacy and safety of the 2 protocols are comparable; the monthly protocol could be used as an alternative to the weekly protocol.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethylprednisoloneGraves OphthalmopathyHumansAdolescentYoung AdultAdultMiddle AgedQuality of LifeProspective StudiesGlucocorticoidsTreatment OutcomeRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Graves orbitopathycorticosteroidsglucocorticoidsnoninferiority evaluationrandomized controlled trials

Substanzen

MethylprednisoloneGlucocorticoids

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Endocrinology and Metabolism, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, Guangdong, China.
  • Department of Endocrinology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

ORCID-Profile: Zhangfang Li, Yaosheng Luo, Chenzhong Li, Tong Zhang, Jie Shen

Förderung

  • Southern Medical University
  • Guangdong Science and Technology Plan Project
  • China Health Promotion Foundation Thyroid Research Project for Young and Middle-aged Doctors
  • Guangdong Province key Field Research and Development Plan Project

Zitieren

APA

Li, Z., Luo, Y., Huang, Q., Chen, Z., Song, D., Pan, D., Hu, S., Jiang, W., Cai, Q., Feng, X., Zhang, Q., Weng, C., Zhong, Q., Zhao, T., Li, C., Zhang, T., & Shen, J. (2023). A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad476

Vancouver

Li Z, Luo Y, Huang Q, Chen Z, Song D, Pan D, et al. A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad476

BibTeX
@article{Li2023,
  author = {Li, Zhangfang and Luo, Yaosheng and Huang, Quandi and Chen, Zhi and Song, Dandan and Pan, Daoyan and Hu, Shidi and Jiang, Wei and Cai, Qiuyue and Feng, Xiaoting and Zhang, Qing and Weng, Chanyan and Zhong, Qiang and Zhao, Tongfeng and Li, Chenzhong and Zhang, Tong and Shen, Jie},
  title = {A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgad476}
}
Kostenlos starten →